Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24739134 | 0.90 | P2RX3 (0.43) | GPR119MCL1P2RX3L3MBTL1 | |
| SCHEMBL24739542 | 0.90 | HRH3 (0.38) | HRH3GPR119MCL1EPHX2TACR1 | |
| SCHEMBL24739228 | 0.90 | P2RX3 (0.43) | GPR119MCL1P2RX3L3MBTL1 | |
| SCHEMBL24739388 | 0.90 | USP30 (0.43) | GPR119MCL1L3MBTL1 | |
| SCHEMBL24739054 | 0.90 | GPR119 (0.42) | HRH3GPR119MCL1P2RX3 | |
| SCHEMBL24739403 | 0.87 | GPR119 (0.41) | HRH3GPR119 | |
| SCHEMBL24739232 | 0.87 | GPR119 (0.41) | HRH3GPR119 | |
| SCHEMBL24739018 | 0.87 | GPR119 (0.37) | GPR119L3MBTL1 | |
| SCHEMBL24739445 | 0.85 | HRH3 (0.43) | HRH3KCNH2GPR119MCL1EPHX2 | |
| SCHEMBL24739165 | 0.81 | ALDH1A1 (0.36) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253101-A1 | PYRIDAZINONE COMPOUND AS PARP7 INHIBITOR | 上海优理惠生医药有限公司 | 2022-12-08 | — | — | WO | disclosed |